MAR 24, 2020 5:51 AM PDT

Ultra sensitive cancer diagnostic detects DNA "fingerprints" in liquid biopsies

WRITTEN BY: Tara Fernandez

Researchers from the Broad and Dana-Farber Cancer Institutes have developed a diagnostic technology that can be used to monitor patients for the presence of recurring cancer cells after receiving treatment. This “liquid biopsy” screening platform is so sensitive, that it can detect metastatic cancer cells years before they would show up using traditional techniques.

The retrospective study, published in Clinical Cancer Research, tracked banked blood samples from breast cancer patients in the years following their initial diagnosis and treatment. Nearly 30 percent of women diagnosed with breast cancer will develop metastatic disease, as a result of cancer cells breaking away from the original tumor in the breast and migrating to other parts of the body through the bloodstream or the lymphatic system.

Senior author Viktor Adalsteinsson and his team first used whole-exome DNA sequencing to identify the unique DNA “fingerprint” from the tumors isolated from each of the 142 patients in the study. Significantly, the researchers found trace amounts of these cancer DNA sequences in the patients’ blood samples up to three years before metastatic cancer recurrence was picked up using standard diagnostic approaches.

“By taking an individualized approach — searching for many mutations that are specific to one patient’s cancer — we could greatly increase our sensitivity to detect traces of cancer DNA in patients who had completed their initial treatment plan,” explained Adalsteinsson.

“And with that sensitivity, we could identify residual cancer from blood samples taken many months to years before a recurring case was diagnosed through standard approaches.”

Future studies are going to employ whole-genome sequencing to boost the test’s sensitivity by collecting more genetic information about the patient’s tumor. In whole-genome sequencing, large amounts of DNA are sequenced at a single time, allowing researchers to perform a more in-depth characterization of the patient’s entire genome. 

With this technology, cancer patients would be able to receive more timely interventions should their cancer return or residual malignant cells be present after their initial treatment.

According to Adalsteinsson, “When we did detect residual disease in blood, following initial courses of treatment, it was a strong predictor of future recurrence. While this was a retrospective study, if a blood biopsy can give clinicians this early warning in real-time, that might provide the opportunity to alter a patient’s outcome.”

 

 


Source: The Harvard Gazette, Clinical Cancer Research.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
APR 11, 2020
Clinical & Molecular DX
The "Smart Toilet": Getting to the Bottom of Precision Health
APR 11, 2020
The "Smart Toilet": Getting to the Bottom of Precision Health
Your toilet could soon play a big part in keeping you healthy, thanks to a new “smart toilet” technology dev ...
APR 23, 2020
Immunology
COVID "Immunity Passports" Are a No-Go
APR 23, 2020
COVID "Immunity Passports" Are a No-Go
  Authorities are caught between dealing with the competing urgencies of abating the COVID-19 health crisis and the ...
JUN 18, 2020
Cancer
The Importance of Timing in the Standard Treatment of Glioma
JUN 18, 2020
The Importance of Timing in the Standard Treatment of Glioma
Glioblastomas, the most common form of brain cancer, are very aggressive and have a standard three-stage treatment. The ...
JUN 26, 2020
Cardiology
Drug for Osteoporosis Linked to Increased Risk of Adverse Cardiovascular Events
JUN 26, 2020
Drug for Osteoporosis Linked to Increased Risk of Adverse Cardiovascular Events
In a recent study done by Jonas Bovijn, MBChB, MSc, DLSHTM, of the Big Data Institute at the University of Oxford’ ...
JUL 16, 2020
Clinical & Molecular DX
AI Platform Alerts to the Earliest Signs of COVID-Related Pneumonia
JUL 16, 2020
AI Platform Alerts to the Earliest Signs of COVID-Related Pneumonia
Severe cases of COVID-19 can cause pneumonia, a process whereby the delicate air sacs in the lungs swell with fluid, and ...
AUG 06, 2020
Cardiology
Identifying a Prognostic Biomarker for Neurological Deterioration After a Stroke
AUG 06, 2020
Identifying a Prognostic Biomarker for Neurological Deterioration After a Stroke
Strokes are life-changing events that can cause a myriad of issues even after it is over. Plenty of tests, such as the n ...
Loading Comments...